ProfileGDS5678 / 1456178_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 56% 57% 58% 58% 57% 60% 56% 60% 57% 59% 58% 57% 54% 58% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4713256
GSM967853U87-EV human glioblastoma xenograft - Control 23.4722557
GSM967854U87-EV human glioblastoma xenograft - Control 33.4950358
GSM967855U87-EV human glioblastoma xenograft - Control 43.461758
GSM967856U87-EV human glioblastoma xenograft - Control 53.4274257
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6877560
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4958156
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6071960
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.4322357
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5086659
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5002858
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.423957
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.362554
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.4893458